Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Rogers, Arizona Clinical Trials

A listing of Rogers, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (4) clinical trials

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Primary Objectives To evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 To evaluate the safety and tolerability of seladelpar in subjects with NASH Secondary Objectives To evaluate the effect of seladelpar on hepatic fat fraction, as ...

Phase

2.67 miles

Learn More »

A Study to Evaluate the Pharmacokinetics Efficacy and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the ...

Phase

4.89 miles

Learn More »

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive Metastatic Castration Resistant Prostate Cancer

This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 portion of the study will determine the recommended dose of 177Lu-PSMA-R2 for radio-ligand therapy (RLT) of mCRPC, ...

Phase

9.76 miles

Learn More »

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Assessment of the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68Ga-PSMA-R2, to assess the pharmacokinetics (PK), biodistribution, and dosimetry of 68Ga-PSMA-R2, and to establish the optimal imaging method for determining location and ...

Phase

9.76 miles

Learn More »